Two other oral BTK inhibitors in development for MS – Merck KGaA’s evobrutinib and Sanofi’s tolebrutinib – have been linked to liver toxicity that resulted in the FDA placing them on ...

Merck KGaA's evobrutinib was the first BTK inhibitor to show proof-of-concept in a phase 2 MS trial, but failed two phase 3 trials in relapsing MS last year and was shelved. Novartis' remibrutinib ...

In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of ...

Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology ...

In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.

Merck (MRK) announced that the European Commission has conditionally approved WELIREG, Merck’s oral hypoxia-inducible factor-2 alpha inhibitor, ...

Gilead (GILD) stock won an upgrade from Deutsche Bank on HIV treatment boost, while Merck (MRK) stock received a downgrade on ...

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other cheap high dividend stocks. According to Deutsche Bank Wealth Management, the global ...

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical ...